Raily Aesthetic Medicine International Holdings Ltd

Raily Aesthetic Medicine International Holdings Ltd maintains a market price of 0.141, with a market capitalization of 78.55 million CNY. The company's price-to-earnings ratio is 41.94, and its price-to-book ratio is 0.73, indicating a relatively low valuation compared to book value. The enterprise value to EBITDA ratio is 40.93, suggesting a high valuation relative to earnings before interest, taxes, depreciation, and amortization. The company's profitability is modest, with a return on equity of 1.74% and a return on assets of 0.79%. These figures are below the industry median for healthcare providers, indicating that the company is not generating strong returns relative to its equity and asset base. The operating income margin is 1.78%, and the net income margin is 0.99%, both of which are low compared to industry benchmarks. The company's revenue is concentrated in the domestic market, with no significant international exposure disclosed. The business is divided into three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products. The Aesthetic Medical Services segment is the largest contributor to revenue, followed by the Aesthetic Medical Equipment Products segment. The Consulting Services segment is the smallest. The company's growth trajectory is mixed. Revenue for the latest period is 189.41 million CNY, with a year-over-year growth rate of 12.3%. However, the outlook for the next fiscal year is for a 5.6% decline in revenue, primarily due to increased competition and regulatory pressures. The company faces several risk factors, including liquidity concerns. The current ratio is 0.77, indicating that the company has more current liabilities than current assets. The debt-to-equity ratio is 0.55, suggesting a moderate level of leverage. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has a negative net cash position after subtracting total debt, which could impact its ability to fund operations and growth initiatives. Recent events include the filing of a 10-K report that highlights the company's exposure to regulatory changes and the potential for increased competition in the aesthetic medical services market. The company has also issued new shares to raise capital for expansion, which could affect shareholder dilution in the near term.